NPS PHARMACEUTICALS INC's ticker is P103PS and the CUSIP is 62936P103. A total of 2 filers reported holding NPS PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2014 | $233,000 | -54.0% | 6,510 | -57.5% | 0.02% | -50.0% |
Q2 2014 | $507,000 | -48.3% | 15,335 | -52.5% | 0.04% | -58.0% |
Q4 2013 | $981,000 | -11.5% | 32,315 | -7.2% | 0.10% | -14.5% |
Q3 2013 | $1,108,000 | +214.8% | 34,830 | +49.5% | 0.12% | +178.6% |
Q2 2013 | $352,000 | – | 23,290 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HARVEY CAPITAL MANAGEMENT INC | 431,475 | $15,433,000 | 5.92% |
SECTORAL ASSET MANAGEMENT INC | 1,623,073 | $58,057,000 | 2.60% |
Palo Alto Investors LP | 1,190,263 | $42,576,000 | 2.50% |
Fiera Capital (Europe) Ltd. | 426,250 | $3,246,000 | 2.39% |
BENDER ROBERT & ASSOCIATES | 75,080 | $2,686,000 | 1.76% |
FCG ADVISORS, LLC | 76,865 | $3,138,000 | 1.55% |
Penn Capital Management Company, LLC | 857,621 | $30,677,000 | 1.29% |
NEXT CENTURY GROWTH INVESTORS LLC | 927,285 | $33,168,000 | 1.20% |
Tekla Capital Management LLC | 625,900 | $22,388,000 | 1.05% |
Orbimed Advisors | 2,954,900 | $105,697,000 | 1.01% |